Herceptin Infusion SC 600 mg/5 mL 1 Vial

 130,000.00

Manufactured by:
Active Pharmaceutical Ingredient:
Drug Strength: 600 mg/5 mL
Drug Form : Infusion SC
Pack Size : 1 vial

Herceptin Infusion SC contains Trastuzumab | belongs to Monoclonal antibody

SKU: pg_10677_14891 Categories: ,

Alternate brands of Herceptin Infusion SC 600 mg/5 mL 1 Vial

Brand Name Price Savings
Kadcyla Infusion 160 mg 1 Vial  354,535.00 You will pay -224535 more
Kadcyla Infusion 100 mg 1 Vial  221,583.00 You will pay -91583 more
Herceptin Injection 440 mg 20 mL  130,000.00 You can save 0
List of alternate brands

Reviews

There are no reviews yet.

Be the first to review “Herceptin Infusion SC 600 mg/5 mL 1 Vial”

How it works

Herceptin Infusion SC 600 mg/5 mL 1 Vial works by stopping the growth of cancer cells in the body.

Side effects

Major & minor side effects for Herceptin Infusion SC 600 mg/5 mL 1 Vial

  • Fever
  • Headache
  • Nausea and Vomiting
  • Tiredness and weakness
  • Shortness of breath
  • Diarrhea
  • Reduction in blood cell count severe
  • Infections severe
  • Muscle and joint pain
  • Increased
  • Swelling of mucous membranes
  • Swelling of the face, lips, or tongue severe
  • Change in taste
  • Sleep disturbances
  • Stomach pain
  • Heartburn and indigestion
  • Depression severe
  • Unusual bleeding or bruising severe
  • Pale skin severe

Uses of Herceptin Infusion SC 600 mg/5 mL 1 Vial

What is it prescribed for?

  • Adjuvant breast cancer

    This medicine is indicated for the treatment of early-stage breast cancer that is human epidermal growth factor receptor-2 positive (HER2+) and has spread to the lymph nodes. It is also used for the treatment of HER2+ cancer that has not spread to the lymph nodes and is estrogen receptor/progesterone receptor negative or with one high-risk feature. This medicine is used either alone or in a combination with other anticancer therapies.

  • Metastatic breast cancer

    This medicine is indicated for the treatment of metastatic breast cancer that is human epidermal growth factor receptor-2 positive (HER2+). It is used either alone or in a combination with other anticancer therapies.

  • Metastatic gastric cancer

    This medicine is indicated for the treatment of metastatic cancer of the stomach or the gastroesophageal junction that is human epidermal growth factor receptor-2 positive (HER2+). It is used in a combination with other anticancer therapies in patients who have not received any prior treatment for the metastatic disease.

Concerns

Frequently asked questions

  • Onset of action

    The amount of time required for this medicine to show its action is not clinically established.

  • Duration of Effect

    The amount of time for which this medicine remains active in the body is not clinically established.

  • Safe with Alchohol?

    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

  • Is it habit forming?

    No habit-forming tendencies were reported.

  • Usage in pregnancy?

    This medicine is not recommended for use in pregnant women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the condition and potential risks and benefits associated with use.

  • Usage while breast-feeding?

    This medicine is not recommended for use in breastfeeding women. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.

When not to use?

  • Allergy

    This medicine is not recommended for use in patients with a known allergy to Herceptin Infusion SC 600 mg/5 mL 1 Vial or any other inactive ingredients present along with it.

Warnings

Warnings for special population
  • Pregnancy

    This medicine is not recommended for use in pregnant women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the condition and potential risks and benefits associated with use.

  • Breast-feeding

    This medicine is not recommended for use in breastfeeding women. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.

General Warnings
  • Cardiovascular disorders

    Usage of this medicine may increase the risk of heart-related complications. Caution is advised while initiating the therapy in patients with any active heart condition. Close monitoring of heart function and vital signs, appropriate dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

  • Infusion reactions

    Usage of this medicine may cause symptoms like fever, chills, nausea, vomiting, dizziness, dyspnea, fall in blood pressure, etc. in some patients. Your doctor may decrease the rate of infusion or discontinue the therapy in such cases and symptomatic treatment will be initiated.

  • Blood cell counts

    Usage of this medicine may alter the levels of blood cell components. Hence, caution is advised while initiating the therapy with this medicine in patients with a pre-existing blood cell disorder. Regular monitoring of blood cell components is advised while this medicine is being administered. An alternative treatment option may be necessary in some cases based on the clinical condition.

  • Lung diseases

    Usage of this medicine may worsen the symptoms of a pre-existing chronic lung disorder. Hence, it should be used with caution in such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition.

  • HER2 testing

    It is recommended to test the overexpression of human epidermal growth factor receptor (HER2) using appropriate laboratory methods before the administration of this medicine is initiated.

  • Women of childbearing potential

    Usage of this medicine during pregnancy or within 7 months prior to the conception may increase the risk of fetal harm. Hence, appropriate and adequate contraception is advised for women of childbearing potential during the treatment and for 7 months following the last dose of this medicine.

  • Driving or Operating machinery

    Use of this medicine may cause blurred vision or dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

  • Tumor lysis syndrome

    Usage of this medicine may increase the risk of tumor lysis syndrome, especially in patients with bulky metastases. Frequent clinical monitoring is required while receiving this medicine. An alternative treatment may be necessary in some cases based on the clinical condition.

Dosage

  • Missed Dose

    Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. If you miss a scheduled appointment for a dose of this medicine, contact your doctor immediately for further instructions.

  • Overdose

    Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.

Interactions

Interaction with Medicines
  • Leflunomide severe
  • Live vaccines severe
  • Etanercept severe
  • Doxorubicin severe
  • Ganciclovir moderate
  • Adalimumab severe
  • Paclitaxel moderate
  • Warfarin moderate
  • Baricitinib severe
Disease interactions
  • severe

    This medicine is not recommended for use in patients who are diagnosed with pneumonitis or interstitial lung disease due to the increased risk of worsening of the patient's condition. Report to your doctor if you are having any pulmonary disorders before receiving this medicine. Usage of this medicine may increase the risk of pulmonary toxicity. An alternative treatment option may be necessary in some cases based on the clinical condition.

  • moderate

    This medicine should be used with caution in patients suffering from cardiovascular diseases due to the increased risk of worsening of the patient’s condition. Regular monitoring of heart function and vital signs may be necessary for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

  • moderate

    This medicine should be used with caution in patients with peripheral neuropathy due to the increased risk of worsening of the patient’s condition. Your doctor may discontinue your therapy if you are diagnosed with grade III or grade IV neuropathy until it is resolved. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition.

  • moderate

    This medicine should be used with caution in patients with decreased platelet counts due to the increased risk of worsening of the patient’s condition. Regular monitoring of platelet count is necessary prior to each dose of this medicine. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition.

General Instructions

This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. The dose quantity and frequency of administration is very specific and should be adhered to. Certain laboratory tests may be needed before, during, and after the treatment with this medicine. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.

Other details

  • Usage does not depend on food timings
  • To be taken as instructed by doctor
  • May cause sleepiness

References

Additional Information>

How to use Herceptin Infusion SC 600 mg/5 mL 1 Vial

Do not give as an IV push or bolus. Administered by IV inf loading doses or infused over 90 min; maintenance doses may be infused over 30 min if tolerated.
Reconstitution: Reconstitute each 440 mg vial with 20 mL of bacteriostatic water for injection, containing benzyl alcohol 1.1% as a preservative, to yield a multidose solution containing trastuzumab 21 mg/mL. In patients with hypersensitivity to benzyl alcohol, reconstitute with 20 mL of SWFI without preservative to yield a single-use solution. Using a sterile syringe, slowly inject 20 mL of the diluents into the vial containing the lyophilized cake of trastuzumab. The stream of diluent should be directed into the lyophilized cake. Swirl the vial gently to aid reconstitution. Do not shake. Slight foaming may be present upon reconstitution. Allow the vial to stand undisturbed for approximately 5 min.
Stability: Vials are stable at 2°C-8°C (36°F-46°F) prior to reconstitution. A vial of trastuzumab reconstituted with bacteriostatic water for injection, as supplied, is stable for 28 days after reconstitution when refrigerated between 2°C-8°C (36°F-46°F). Discard any remaining multidose reconstituted solution after 28 days. A vial of trastuzumab reconstituted with unpreserved SWFI should be used within 24 hours. Discard any unused portion. The solution of trastuzumab for infusion diluted in polyvinyl chloride or polyethylene bags containing 0.9% NaCl should be stored between 2°C-8°C (36°F-46°F) for no more than 24 hours prior to use. Do not freeze reconstituted or diluted solutions.

what are the adverse effects of Herceptin Infusion SC 600 mg/5 mL 1 Vial?

Headache, neutropenia, sepsis, CNS disorders, GI upsets, skin reactions, pneumonia, renal disorders, hepatitis, oedema, anorexia, weight loss, flu-like syndrome.

What happens if I miss a dose of Herceptin Infusion SC 600 mg/5 mL 1 Vial?

Metastatic breast cancer: Adults: 4 mg/kg by IV infusion over 90 min. Maint: 2 mg/kg IV over 30 min every wk.

One of the following licensed pharmacy from the nearest location will deliver Herceptin Infusion SC 600 mg/5 mL 1 Vial. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.

Questions and Answers

There are no questions yet. Be the first to ask a question about this product.

Only registered users are eligible to enter questions

Medicalstore.com.pk © All rights reserved

Made with ❤ by Dairah

Shopping Cart